Johns Hopkins University

Peter M Abadir

Jeremy D Walston

Honggang Cui

Andrew G Cheetham

Neal Fedarko

Alka Jain

Ran Lin

Provided herein is a novel mitochondrial Angiotensin II type 1 and type 2 ATR and ATR receptor which plays a role in protection of mitochondria against oxidative damage. Evidence from animal studies indicates a role for this receptor in preservation of mitochondria and up-regulation of survival genes, anti-inflammatory action, and improvement of wound healing in the skin and soft tissues. Pharmaceutical compositions for treatment directed to preserving mitochondrial function, anti-inflammation, wound healing and decreasing the signs of aging, as well as medicaments and their use are also provided.

Protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair

The invention described herein provides novel ampiphilic compounds that self-assemble into a hydrogel composition useful for treating wounds, including chronic wounds and diabetic wounds. The compounds of the invention have structural characteristics, such as hydrophilic and hydrophobic moieties, that enable self-assembly into discrete nanostructures, which then entangle to form the hydrogel. Also provided are methods for treating wounds.

Supramolecular hydrogels containing angiotensin receptor blockers for targeted treatment of diabetic wounds

The invention described herein provides methods for treating a disease or disorder associated with angiotensin receptor signaling in a patient exhibiting elevated levels of ATIR autoantibodies. The invention also provides methods of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker. Patients with elevated levels of ATIR autoantibodies are identified as candidates that particularly benefit from treatment with an angiotensin receptor blocker.

Angiotensin receptor autoantibodies as biomarker for effected usage of angiotensin receptor blockers

The present invention provides compounds and a method for the targeted delivery of Mitochondrial Angiotensin Receptor Blockers (MARBs) to the Mitochondrial Angiotensin System (MAS) for the treatment of diseases caused by angiotensin-related mitochondrial dysfunction. The compounds include a mitochondrial targeting signal, a residue of a drug molecule, a functional moiety, and a scaffold moiety.

Growing community of inventors

Woodstock, MD, United States of America

Peter M Abadir